Post by PressReleaseon Dec 22, 2022 2:01pm
29 Views
Post# 35187631
New Press Release - Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19